Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$240.74 USD

240.74
203,030

+0.75 (0.31%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $240.81 +0.07 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Masimo and Saudi Arabia MOH Collaborate for CCHD Screening

by Zacks Equity Research

Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.

Zacks Equity Research

Luminex Hurt By Segmental Sluggishness, Stiff Competition

by Zacks Equity Research

Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.

Zacks Equity Research

Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose

by Zacks Equity Research

The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.

Zacks Equity Research

Align Technology Unveils iTero Element 5D Imaging System

by Zacks Equity Research

Align Technology (ALGN) continues to expand work flow options of iTero scanners.

Zacks Equity Research

Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

by Zacks Equity Research

Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

Zacks Equity Research

NHNKY vs. PEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

NHNKY vs. PEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why Investors Should Buy CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

Zacks Equity Research

Boston Scientific Benefits From New Buyouts & Product Launch

by Zacks Equity Research

Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

Zacks Equity Research

Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

by Zacks Equity Research

The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

Zacks Equity Research

Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

by Zacks Equity Research

IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

Zacks Equity Research

Cardinal Health Strong on Pharmaceutical, Competition Rife

by Zacks Equity Research

Cardinal Health (CAH) is on track to deliver targeted annualized cost savings of $100 million in fiscal 2019.

Zacks Equity Research

Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance

by Zacks Equity Research

Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.

Zacks Equity Research

BD Gains From Solid Global Base, Headwinds Anticipated

by Zacks Equity Research

Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.

Zacks Equity Research

HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.

Zacks Equity Research

NHNKY vs. PEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

NHNKY vs. PEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Varian Medical's (VAR) ProBeam Compact Picked by Biopolis

by Zacks Equity Research

The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.

Zacks Equity Research

Here's Why Investors Should Hold AngioDynamics (ANGO) Now

by Zacks Equity Research

AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.

Zacks Equity Research

Here's Why You Should Invest in OPKO Health (OPK) Right Now

by Zacks Equity Research

OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining strength from the In Vitro Diagnostics (IVD) unit. The segment is a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

Zacks Equity Research

Here's Why You Should Invest in Veeva Systems (VEEV) Now

by Zacks Equity Research

Veeva Systems' (VEEV) focus on cloud-based systems like Veeva Vault makes it a solid pick.

Zacks Equity Research

Masimo's (MASI) Preliminary Results for 2018 Cheer Investors

by Zacks Equity Research

Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.

Zacks Equity Research

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Intuitive Surgical (ISRG) is likely to gain from solid da Vinci contributions in fourth-quarter 2018.

Zacks Equity Research

Allscripts (MDRX) Collaborates With Microsoft, Shares Up

by Zacks Equity Research

Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.

Zacks Equity Research

Luminex's (LMNX) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

Luminex (LMNX) likely to gain from strong segmental contributions in Q4.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Exclusion of Varian Medical's (VAR) flagship Halcyon from Section 301 tariffs lends it a competitive edge in the MedTech space.